



Roche
Foundation
for Anemia
Research

New research in anemia—First call for funding applications

Apply to the Roche Foundation for Anemia Research (RoFAR) for funding of new research in areas associated with the study of anemia.

Eligibility

Grant applications are open to established members of academic staff at universities, dialysis centers and research institutes. Applications should focus on the need to improve outcomes and encourage scientific advances relating to the following research areas:

- Anemia related to kidney disease, oncology and other chronic diseases
- Extra erythropoetic effects e.g. neuroprotective effect of substances used for treatment of anemia

Applying for a grant

All applicants must initially provide a Letter of Intent to the RoFAR.

The Letter of Intent should include: applicant details, title, summary, and, included in a ~500 word abstract, description of the planned research (objective, background, hypothesis /specific aims, preliminary results (if available), proposed methodology), and estimated funding requirements.

Initial applications will be reviewed and evaluated by the Scientific Advisory Board following several criteria including: relevance to the objectives of the Foundation, feasibility, scientific excellence and originality.

Based on the ranking of the Letters of Intent, selected applicants will be invited by the RoFAR to submit a full application.

**All submissions should be made via the
RoFAR website www.rofar.org**

**The first deadline for submitting a Letter of Intent is
30th June 2004**

Awards

The first round of awards will be announced at the end of 2004.

About the foundation

The Roche Foundation for Anemia Research, RoFAR, is a non-profit, independent, charitable funding body that aims to 'encourage innovative research that will open new avenues of exploration in the study of anemia'.

The funding of the Foundation consists of donations from F. Hoffmann-La Roche Ltd., with an initial sum of 16 million Swiss Francs over the first four years. The Foundation structure involves eight Trustees, from both renal and oncology spheres and a Scientific Advisory Board.

The Foundation is legally independent from F. Hoffmann-La Roche Ltd. and is guided solely by the Board of Trustees according to its charter.

Board of Trustees: Nathan Levin, USA (Chair), James Armitage, USA, Charles Herzog, USA, Adeera Levin, Canada, Jean François Morere, France, Neil Powe, USA, Eberhard Ritz, Germany, Lars Birgerson, USA